These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 21118955)

  • 1. In vivo characterization of MMP-2200, a mixed δ/μ opioid agonist, in mice.
    Lowery JJ; Raymond TJ; Giuvelis D; Bidlack JM; Polt R; Bilsky EJ
    J Pharmacol Exp Ther; 2011 Mar; 336(3):767-78. PubMed ID: 21118955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral pharmacology of the mu/delta opioid glycopeptide MMP2200 in rhesus monkeys.
    Do Carmo GP; Polt R; Bilsky EJ; Rice KC; Negus SS
    J Pharmacol Exp Ther; 2008 Sep; 326(3):939-48. PubMed ID: 18511649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice.
    Bilsky EJ; Inturrisi CE; Sadée W; Hruby VJ; Porreca F
    Pain; 1996 Dec; 68(2-3):229-37. PubMed ID: 9121809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
    Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
    Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral pharmacology of the mixed-action delta-selective opioid receptor agonist BBI-11008: studies on acute, inflammatory and neuropathic pain, respiration, and drug self-administration.
    Stevenson GW; Giuvelis D; Cormier J; Cone K; Atherton P; Krivitsky R; Warner E; St Laurent B; Dutra J; Bidlack JM; Szabò L; Polt R; Bilsky EJ
    Psychopharmacology (Berl); 2020 Apr; 237(4):1195-1208. PubMed ID: 31912192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Mu-Delta Opioid Agonist Demonstrates Enhanced Efficacy With Reduced Tolerance and Dependence in Mouse Neuropathic Pain Models.
    Lei W; Vekariya RH; Ananthan S; Streicher JM
    J Pain; 2020; 21(1-2):146-160. PubMed ID: 31201990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo effects of μ-opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administration.
    Anand JP; Kochan KE; Nastase AF; Montgomery D; Griggs NW; Traynor JR; Mosberg HI; Jutkiewicz EM
    Br J Pharmacol; 2018 Jun; 175(11):2013-2027. PubMed ID: 29352503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice.
    Bilsky EJ; Bernstein RN; Wang Z; Sadée W; Porreca F
    J Pharmacol Exp Ther; 1996 Apr; 277(1):484-90. PubMed ID: 8613958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term Mu-selective irreversible opioid antagonist.
    Xu JY; Seyed-Mozaffari A; Archer S; Bidlack JM
    J Pharmacol Exp Ther; 1996 Nov; 279(2):539-47. PubMed ID: 8930155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between the mu-agonist dermorphin and the delta-agonist [D-Ala2, Glu4]deltorphin in supraspinal antinociception and delta-opioid receptor binding.
    Negri L; Improta G; Lattanzi R; Potenza RL; Luchetti F; Melchiorri P
    Br J Pharmacol; 1995 Dec; 116(7):2931-8. PubMed ID: 8680727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.
    Healy JR; Bezawada P; Shim J; Jones JW; Kane MA; MacKerell AD; Coop A; Matsumoto RR
    ACS Chem Neurosci; 2013 Sep; 4(9):1256-66. PubMed ID: 23713721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior.
    Wang YJ; Tao YM; Li FY; Wang YH; Xu XJ; Chen J; Cao YL; Chi ZQ; Neumeyer JL; Zhang A; Liu JG
    J Pharmacol Exp Ther; 2009 Apr; 329(1):306-13. PubMed ID: 19136637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice.
    Ide S; Minami M; Satoh M; Uhl GR; Sora I; Ikeda K
    Neuropsychopharmacology; 2004 Sep; 29(9):1656-63. PubMed ID: 15100703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orally active opioid μ/δ dual agonist MGM-16, a derivative of the indole alkaloid mitragynine, exhibits potent antiallodynic effect on neuropathic pain in mice.
    Matsumoto K; Narita M; Muramatsu N; Nakayama T; Misawa K; Kitajima M; Tashima K; Devi LA; Suzuki T; Takayama H; Horie S
    J Pharmacol Exp Ther; 2014 Mar; 348(3):383-92. PubMed ID: 24345467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of delta-opioid receptor contributes to the antinociceptive effect of oxycodone in mice.
    Yang PP; Yeh GC; Yeh TK; Xi J; Loh HH; Law PY; Tao PL
    Pharmacol Res; 2016 Sep; 111():867-876. PubMed ID: 27496654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antinociceptive effects of the 6-O-sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors.
    Yadlapalli JSK; Ford BM; Ketkar A; Wan A; Penthala NR; Eoff RL; Prather PL; Dobretsov M; Crooks PA
    Pharmacol Res; 2016 Nov; 113(Pt A):335-347. PubMed ID: 27637375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice.
    Ward SJ; Takemori AE
    J Pharmacol Exp Ther; 1983 Mar; 224(3):525-30. PubMed ID: 6131119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dmt(1)]DALDA is highly selective and potent at mu opioid receptors, but is not cross-tolerant with systemic morphine.
    Riba P; Ben Y; Nguyen TM; Furst S; Schiller PW; Lee NM
    Curr Med Chem; 2002 Jan; 9(1):31-9. PubMed ID: 11860345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and Pharmacological Characterization of a Low-Liability Antinociceptive Bifunctional MOR/DOR Cyclic Peptide.
    Li Y; Eans SO; Ganno-Sherwood M; Eliasof A; Houghten RA; McLaughlin JP
    Molecules; 2023 Nov; 28(22):. PubMed ID: 38005269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.